Semaglutide, specifically the brand Ozempic, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D. It is also indicated to reduce risk for major adverse cardiovascular events (eg, cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with T2D and established cardiovascular disease. Some patients may prefer oral administration (Rybelsus) over the subcutaneous form, and neither is recommended above the other.
Learn more about semaglutide for T2D.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Semaglutide - Medscape - Jan 20, 2022.
Comments